Research conducted by Masahiro et al. showed that DC vaccines loaded with Wilms’ tumor 1 (WT1) enhance immune surveillance by reducing the number of MDSCs and downregulating their immunosuppressive functions, particularly the arginase 1 and IDO pathways, offering new hope for immunotherapy in AML [172]. Here, ARG1 is linked to acute myeloid leukemia.